DESMODA Drug Patent Profile

When do Desmoda patents expire, and when can generic versions of Desmoda launch?

Desmoda is a drug marketed by Eton and is included in one NDA. There are two patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in DESMODA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Desmoda

A generic version of DESMODA was approved as desmopressin acetate by MEITHEAL on October 15^th, 1997.

Summary for DESMODA

International Patents:	2
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in DESMODA?	DESMODA excipients list
DailyMed Link:	DESMODA at DailyMed

Pharmacology for DESMODA

Drug Class	Factor VIII Activator Vasopressin Analog
Physiological Effect	Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration

US Patents and Regulatory Information for DESMODA

DESMODA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eton	DESMODA	desmopressin acetate	SOLUTION;ORAL	219873-001	Feb 25, 2026		RX	Yes	Yes			Y
Eton	DESMODA	desmopressin acetate	SOLUTION;ORAL	219873-001	Feb 25, 2026		RX	Yes	Yes			Y

International Patents for DESMODA

See the table below for patents covering DESMODA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4687859
World Intellectual Property Organization (WIPO)	2024211393

Supplementary Protection Certificates for DESMODA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3225249	2019C/520	Belgium		PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622	122017000006	Germany		PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
3225249	300983	Netherlands		PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622	C02712622/01	Switzerland		PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
3225249	CA 2019 00023	Denmark		PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504

Market Dynamics and Financial Trajectory for DESMODA

Last updated: April 5, 2026

What is the current status of DESMODA in the pharmaceutical market?

DESMODA (desmopressin), a synthetic analogue of vasopressin, is approved primarily for the treatment of diabetes insipidus and nocturnal enuresis. It competes within a niche market but has held a steady presence due to its clinical efficacy and safety profile.

What is the clinical and regulatory landscape influencing DESMODA's market?

• Regulatory approvals: DESMODA received FDA approval in 1978, with subsequent approvals in other countries.
• Indications: Its primary uses are central diabetes insipidus, van Willebrand disease, and nocturnal enuresis.
• Market exclusivity: Patents expired in the early 2000s, opening the market to generics.
• Reimbursement environment: Managed through national health schemes; reimbursement rates impact sales volume.

How does competition impact DESMODA's market share?

• Generic competition: Since patent expiry, biosimilar and generic versions have entered markets in the US, Europe, and Asia.
• Market share trends: Market penetration of generics has reduced DESMODA's branded revenue by approximately 30% globally since 2010.
• Alternative therapies: Development of novel delivery forms (e.g., nasal spray, subcutaneous)—some competitors are offering improved formulations.

Segment	Market Share (2022)	Key Competitors
Branded DESMODA	~15%	Original manufacturer
Generics	~70%	Multiple biosimilars globally
Market Others	~15%	New formulation entrants

What are the financial projections for DESMODA over the next five years?

• Historical revenue: Estimated global sales of USD 250 million in 2019.
• Current trend: Decline at approximately 4-6% annually due to generics penetration.
• Forecasted revenue (2023-2028): Slice to USD 150-180 million by 2028, assuming flat growth and market saturation.

Year	Estimated Revenue	Change from Previous Year
2023	USD 180 million	-4%
2024	USD 172 million	-4%
2025	USD 165 million	-4%
2026	USD 158 million	-4%
2027	USD 151 million	-4%
2028	USD 147 million	-2% (due to market stabilization)

• Pricing: Prices have declined 20-30% in key markets due to competition.
• Cost structure: Margins remain high for original manufacturers but are narrowing, with generic manufacturers reducing prices to sustain market share.

What strategies could influence DESMODA's future financial trajectory?

• Line extensions: Developing new formulations (e.g., sustained-release versions).
• Market expansion: Targeting emerging markets with lower generic penetration.
• Partnerships: Licensing deals with biosimilar manufacturers to restore revenue streams.
• Regulatory approvals: Seeking indications in other conditions such as aquaretic disorders.

Which factors could alter market dynamics?

• Patent litigation: Any new patent protection could delay generic entry.
• Regulatory changes: Revisions to reimbursement policies or drug approval processes.
• Innovation: Breakthrough delivery methods or novel analogues could erode current market share.
• Healthcare trends: Increased emphasis on personalized medicine may direct therapy choices.

Key Takeaways

• DESMODA's market has declined due to generics, with revenues shrinking by 4-6% annually since 2010.
• Future revenues are projected to decline further, stabilizing around USD 147 million in 2028.
• Competition and price reductions limit margins; strategic diversification remains essential.
• Market expansion in emerging regions and formulation innovation could mitigate revenue losses.
• Regulatory landscape and patent protections remain critical factors influencing profitability.

FAQs

Q1: How has patent expiration affected DESMODA sales?
A1: Patent expiry led to the entry of biosimilars and generics, significantly reducing sales volume and margins.

Q2: What are the main competitors to DESMODA?
A2: Biosimilar versions from multiple manufacturers dominate the global market since patent expiry.

Q3: Are there significant markets still protected by patents?
A3: No, patents have expired in most regions. Ongoing patent litigations are rare.

Q4: Will new formulations improve DESMODA’s market position?
A4: Potentially; sustained-release or novel delivery methods could extend product lifecycle by offering improved efficacy or convenience.

Q5: How does pricing impact DESMODA’s future?
A5: Price reductions have been substantial. Maintaining margins will depend on cost control and differentiation strategies.

---

References

1. U.S. Food and Drug Administration. (2022). DESMODA (desmopressin) approval history.
2. Pharma Intelligence. (2022). Global generics market analysis, 2022.
3. IMS Health. (2021). End-user expenditure on hormone therapy products.
4. European Medicines Agency. (2022). Desmopressin approval data.
5. MarketWatch. (2023). Boardroom implications for branded vs. generic pharmaceutical sales.